CurveBeam AI turns China clearance into first HiRise order

CurveBeam AI has received its first Chinese order for four HiRise weight-bearing CT systems from Weiying/Wego Orthopedics, turning regulatory clearance into an initial commercial foothold. The order value and delivery schedule were not disclosed, while a further A$1 million milestone investment is expected this quarter.

  • First Chinese order for four HiRise weight-bearing CT systems
  • Order received from exclusive distribution partner Weiying/Wego Orthopedics
  • Initial commercial step following NMPA clearance
  • A$1 million milestone investment expected this quarter at A$0.405 per share
  • Order value, delivery timing and revenue impact remain undisclosed
An image related to Curvebeam AI Limited A photo of the logo for Curvebeam AI Add us as a preferred source on Google
Image © middle. Logo © respective owner.

First Four-System China Order

CurveBeam AI Limited (ASX:CVB) has moved from regulatory approval to initial commercial execution in China, receiving an order for four HiRise weight-bearing CT systems from its distribution partner Weiying/Wego Orthopedics. The order is the first for HiRise in the Chinese market, although CurveBeam AI has not disclosed its value, payment terms or expected delivery schedule.

The systems are designed to capture three-dimensional imaging of the lower limb while patients stand under natural bilateral weight-bearing conditions. That capability is central to CurveBeam AI’s pitch for HiRise, which combines specialised CT equipment with AI-enabled clinical assessment software for musculoskeletal care.

NMPA Clearance Opens Commercial Phase

The order follows China’s NMPA clearance for HiRise announced in October and advances the company’s long-term exclusive distribution agreement with Weiying/Wego, covering China, Hong Kong, Macau and Taiwan. The regulatory milestone had been identified as a trigger for the next stage of the partnership, after the company reported its China clearance milestone alongside other commercial and funding developments.

Chief executive Greg Brown described the four-system order as “an important commercial step” and said it represented progress from an agreement with Weiying/Wego to commercial execution. The company said future product sales could follow as market adoption develops, but the announcement does not provide enough information to assess the pace or scale of that adoption.

A$1 Million Milestone Investment Still Pending

CurveBeam AI also expects to receive a further A$1 million milestone investment this quarter at an issue price of A$0.405 per share. The company said the payment remains expected within the quarter, while warning that international banking processes can occasionally cause delays.

For shareholders, the immediate test is whether the initial order converts into installed systems and recognised revenue, rather than simply adding to the partnership’s pipeline. The next signals will be confirmation of the milestone funding, delivery and installation details, and whether Weiying/Wego places additional orders across the territories covered by its exclusive arrangement.

Get ASX:CVB news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The first order gives CurveBeam AI an early commercial proof point in China, but its financial significance will depend on delivery, revenue recognition and follow-on demand.

Questions in the middle?

  • When will the four HiRise systems be delivered and installed, and when will revenue be recognised?
  • Will the expected A$1 million milestone investment arrive within the quarter?
  • Does the initial four-system order lead to a broader rollout through Weiying/Wego’s regional network?

Sources

1